Report cover image

Global Thrombosis Drugs Market Growth, Size, Trends Analysis - By Drug Class, By Disease Type, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034

Publisher SPER Market Research Pvt. Ltd.
Published Jun 23, 2025
Length 244 Pages
SKU # SPER20222483

Description

Thrombosis Drugs Market Introduction and Overview

According to SPER market research, ‘Global Thrombosis Drugs Market Size- By Drug Class, By Disease Type, By Route of Administration, By Distribution Channel – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global Thrombosis Drugs Market is predicted to reach 76 billion by 2034 with a CAGR of 8.43%.

Thrombosis drugs stop platelets from working to prevent clots and new clot formation. They help prevent conditions like arterial fibrillation and deep vein thrombosis. Side effects can include bleeding, vomiting, heavy menstrual periods, and nosebleeds. Thrombotic treatment aims to dissolve clots and includes blood thinners like heparin and warfarin.

Restraints:

Strong anticoagulant side effects are a significant barrier to market growth. Thrombosis drugs, commonly known as anticoagulants or blood thinners, are necessary treatments for preventing and treating cardiovascular emergencies such deep vein thrombosis (DVT) and pulmonary embolism. These medications function by suppressing the body’s natural blood clotting process, enabling blood to flow freely while preventing new clots from forming. However, their use carries hazards such as increased bleeding, particularly in trauma instances.

Scope of the report:

Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034

Segments covered

By Drug Class, By Disease Type, By Route of Administration, By Distribution Channel

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Amgen Inc, Aspen Pharmacare Holdings Limited, Baxter International Inc, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc, Novartis AG, Pfizer Inc.

Global Thrombosis Drugs Market Segmentation:

By Drug Class: Based on the Drug Class, Global Thrombosis Drugs Market is segmented as; Anticoagulants, Antiplatelet Drugs, Thrombolytic Drugs.

By Disease Type: Based on the Disease Type, Global Thrombosis Drugs Market is segmented as; Venous thromboembolism, Deep vein thrombosis, Pulmonary embolism, Arterial thrombosis, Other disease types.

By Route of Administration: Based on the Route of Administration, Global Thrombosis Drugs Market is segmented as; Oral, Parenteral, Topical.

By Distribution Channel:

Based on the Distribution Channel, Global Thrombosis Drugs Market is segmented as; Hospital pharmacies, Retail pharmacies, Online pharmacies.

By Region:

This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

244 Pages
1. Introduction
1.1. Scope of the report
1.2 . Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERs internal database
2.1.4 . Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 . Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Thrombosis Drugs Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Thrombosis Drugs Market
7. Global Thrombosis Drugs Market, By Drug Class (USD Million) 2021-2034
7.1. Anticoagulants
7.1.1. Direct oral anticoagulants
7.1.2. Heparin
7.1.3. Vitamin K antagonists
7.1.4. Xa Inhibitor
7.2. Antiplatelet drugs
7.2.1. P2 Y12 platelet inhibitor
7.2.2. Aspirin
7.2.3. Glycoprotein IIb/IIIa inhibitors
7.3. Thrombolytic drugs
8. Global Thrombosis Drugs Market, By Disease Type (USD Million) 2021-2034
8.1. Venous thromboembolism
8.2. Deep vein thrombosis
8.3. Pulmonary embolism
8.4. Arterial thrombosis
8.5. Other disease types
9. Global Thrombosis Drugs Market, By Route of Administration (USD Million) 2021-2034
9.1. Oral
9.2. Parenteral
9.3. Topical
10. Global Thrombosis Drugs Market, By Distribution Channel (USD Million) 2021-2034
10.1. Hospital pharmacies
10.2. Retail pharmacies
10.3. Online pharmacies
11. Global Thrombosis Drugs Market, (USD Million) 2021-2034
11.1. Global Thrombosis Drugs Market Size and Market Share
12. Global Thrombosis Drugs Market, By Region, (USD Million) 2021-2034
12.1. Asia-Pacific
12.1.1. Australia
12.1.2. China
12.1.3 . India
12.1.4 . Japan
12.1.5. South Korea
12.1.6. Rest of Asia-Pacific
12.2. Europe
12.2.1. France
12.2.2. Germany
12.2.3. Italy
12.2.4. Spain
12.2.5 . United Kingdom
12.2.6 . Rest of Europe
12.3. Middle East and Africa
12.3.1. Kingdom of Saudi Arabia
12.3.2. United Arab Emirates
12.3.3. Qatar
12.3.4. South Africa
12.3.5. Egypt
12.3.6. Morocco
12.3.7. Nigeria
12.3.8. Rest of Middle-East and Africa
12.4. North America
12.4.1. Canada
12.4.2. Mexico
12.4.3. United States
12.5. Latin America
12.5.1. Argentina
12.5.2. Brazil
12.5.3. Rest of Latin America
13. Company Profile
13.1. Amgen Inc
13.1.1. Company details
13.1.2 . Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. Aspen Pharmacare Holdings Limited
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. Baxter International Inc
13.3.1. Company details
13.3.2. Financial outlook
13.3.3 . Product summary
13.3.4. Recent developments
13.4. Bayer AG
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. Boehringer Ingelheim GmbH
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. Bristol-Myers Squibb Company
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. Daiichi Sankyo Company, Limited
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. GlaxoSmithKline plc
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. Janssen Pharmaceuticals, Inc
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. Pfizer Inc
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
13.11. Others
14. Conclusion
15. List of Abbreviations
16. Reference Links

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us